11509 related articles for article (PubMed ID: 14609222)
1. Dendritic cells: controllers of the immune system and a new promise for immunotherapy.
Banchereau J; Fay J; Pascual V; Palucka AK
Novartis Found Symp; 2003; 252():226-35; discussion 235-8, 257-67. PubMed ID: 14609222
[TBL] [Abstract][Full Text] [Related]
2. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
Banchereau J; Palucka AK; Dhodapkar M; Burkeholder S; Taquet N; Rolland A; Taquet S; Coquery S; Wittkowski KM; Bhardwaj N; Pineiro L; Steinman R; Fay J
Cancer Res; 2001 Sep; 61(17):6451-8. PubMed ID: 11522640
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cells from bench to bedside and back.
Adema GJ
Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337
[TBL] [Abstract][Full Text] [Related]
5. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus.
Bayry J; Lacroix-Desmazes S; Delignat S; Mouthon L; Weill B; Kazatchkine MD; Kaveri SV
Arthritis Rheum; 2003 Dec; 48(12):3497-502. PubMed ID: 14674000
[TBL] [Abstract][Full Text] [Related]
7. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12.
Okada N; Iiyama S; Okada Y; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
Cancer Gene Ther; 2005 Jan; 12(1):72-83. PubMed ID: 15389286
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell subsets generated from CD34+ hematopoietic progenitors can be transfected with mRNA and induce antigen-specific cytotoxic T cell responses.
Ueno H; Tcherepanova I; Reygrobellet O; Laughner E; Ventura C; Palucka AK; Banchereau J
J Immunol Methods; 2004 Feb; 285(2):171-80. PubMed ID: 14980432
[TBL] [Abstract][Full Text] [Related]
9. Current concepts in immunotherapy for the treatment of colorectal cancer.
Indar A; Maxwell-Armstrong CA; Durrant LG; Carmichael J; Scholefield JH
J R Coll Surg Edinb; 2002 Apr; 47(2):458-74. PubMed ID: 12018689
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells as vectors for immunotherapy of cancer.
Paczesny S; Ueno H; Fay J; Banchereau J; Palucka AK
Semin Cancer Biol; 2003 Dec; 13(6):439-47. PubMed ID: 15001163
[TBL] [Abstract][Full Text] [Related]
11. Cellular immunotherapy with dendritic cells in cancer: current status.
Nencioni A; Brossart P
Stem Cells; 2004; 22(4):501-13. PubMed ID: 15277696
[TBL] [Abstract][Full Text] [Related]
12. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
Klippstein R; Pozo D
Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
[TBL] [Abstract][Full Text] [Related]
13. Flt3 ligand promotes myeloid dendritic cell differentiation of human hematopoietic progenitor cells: possible application for cancer immunotherapy.
Harada S; Kimura T; Fujiki H; Nakagawa H; Ueda Y; Itoh T; Yamagishi H; Sonoda Y
Int J Oncol; 2007 Jun; 30(6):1461-8. PubMed ID: 17487367
[TBL] [Abstract][Full Text] [Related]
14. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells.
Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M
Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057
[TBL] [Abstract][Full Text] [Related]
15. Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously.
Shojaeian J; Jeddi-Tehrani M; Dokouhaki P; Mahmoudi AR; Ghods R; Bozorgmehr M; Nikoo S; Bayat AA; Akhondi MM; Ostadkarampour M; Rezania S; Zarnani AH
J Immunother; 2009 May; 32(4):325-32. PubMed ID: 19342973
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell immunotherapy: mapping the way.
Figdor CG; de Vries IJ; Lesterhuis WJ; Melief CJ
Nat Med; 2004 May; 10(5):475-80. PubMed ID: 15122249
[TBL] [Abstract][Full Text] [Related]
17. Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity.
Rizza P; Moretti F; Belardelli F
Autoimmunity; 2010 Apr; 43(3):204-9. PubMed ID: 20187707
[TBL] [Abstract][Full Text] [Related]
18. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells.
Eloranta ML; Lövgren T; Finke D; Mathsson L; Rönnelid J; Kastner B; Alm GV; Rönnblom L
Arthritis Rheum; 2009 Aug; 60(8):2418-27. PubMed ID: 19644885
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
Katano M; Morisaki T; Koga K; Nakamura M; Onishi H; Matsumoto K; Tasaki A; Nakashima H; Akiyoshi T; Nakamura M
Anticancer Res; 2005; 25(6A):3771-6. PubMed ID: 16302738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
